The U.S. Food and Drug Administration has approved Wegovy® pill (oral semaglutide) as the first once-daily oral glucagon-like peptide-1 (GLP-1) receptor agonist for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. The approval also includes a claim for reducing the risk of major adverse cardiovascular events in patients with established cardiovascular disease and obesity/overweight, expanding its role beyond weight reduction. 

The approval is grounded in data from the OASIS 4 phase 3 trial, where participants receiving oral semaglutide demonstrated a mean weight loss of about 16.6 %, with approximately one-third achieving ≥20 % weight reduction when adherent to therapy. The efficacy and safety profile in this study were like that seen with the injectable Wegovy formulation, and the oral pill was well tolerated overall. 

Key Clinical Considerations:

• Patient Selection: Indicated for adults with obesity (BMI ≥ 30 kg/m²) or overweight (BMI ≥ 27 kg/m²) with at least one weight-related comorbidity, and for those with established cardiovascular disease to reduce risk of major adverse events.
• Efficacy: Comparable weight loss to injectable GLP-1 therapy in clinical trials - significant mean reductions in body weight with typical semaglutide class GI tolerability profile. 
• Dosing & Use: Once-daily oral tablet; may lower barriers for patients reluctant to start injections and eliminates the need for cold storage, potentially improving adherence. 
• Integration with Lifestyle: As with all anti-obesity medications, oral GLP-1 should be prescribed alongside diet, physical activity, and behavioral support. 
• Access & Cost: Novo Nordisk has rolled out self-pay pricing and copay assistance programs; real-world access will evolve as insurers update coverage policies.

For clinicians, the expansion of GLP-1 therapy into an oral form marks a significant evolution in obesity management, offering a potent, evidence-based option that may broaden patient acceptance and engagement in long-term weight care strategies.

Click here for more information.